Pay in 4 interest-free payments of $7.11 Learn more
Ships within 48 hours ยท Estimated delivery Jul 31 - Aug 5
(Source: Novo Nordisk) In September 2024: Eli Lilly reported positive Phase 3 results for retatrutide, a novel triple GLP-1/GIP/glucagon receptor agonist, demonstrating an average weight loss of 24.2% at 48 weeks in adults with obesity, representing the highest weight loss achieved with any pharmacological agent to date and approaching bariatric surgery efficacy
More than 20 million doses of GLP-1 medication were used worldwide in 2023 (Vinfuture)
Pharmacological approaches to glycemic treatments: standards of care in diabetes 2023
Converting fat into energy
These accredited facilities provide physician-supervised treatments utilizing appetite suppressants (phentermine), fat absorption inhibitors (Orlistat), and GLP-1 receptor agonists (liraglutide)
US$ 25.56
US$ 23.43
US$ 27.73
US$ 21.95
US$ 27.46
US$ 26.65
US$ 29.05
US$ 28.31
US$ 26.80
